FL H0269

Creates the "Right to Try Act" allowing eligible patients with terminal conditions to access investigational drugs, biological products, or devices that have completed phase 1 clinical trials but are not FDA-approved.

Establishes eligibility requirements including attestation of terminal condition by treating physician plus independent board-certified physician confirmation, consideration of all FDA-approved treatments, and written informed consent.

Permits manufacturers to provide investigational treatments with or without compensation, allows patients to pay manufacturing costs, and permits health plans to voluntarily cover related costs.

Protects physicians from licensing board action and prevents lawsuits against manufacturers and healthcare providers who comply in good faith with the act's terms and exercise reasonable care.

Clarifies that heirs are not liable for outstanding debts if patient dies during treatment and that the act does not expand required insurance coverage or affect clinical trial participation mandates; effective July 1, 2015.